Medical technology company ConforMIS, Inc. (NASDAQ: CFMS) has developed a knee replacement system that promises to drastically reduce both the length of the average knee replacement surgery as well as the patient recovery time.

Likely stemmed by the recent drop in their share price, Organovo put forth a detailed explanation for their secondary offering of $40 million in shares, explaining why they’ve taken this route, and what it will mean for their 3D printed human tissue moving forward. 

Organovo Holdings, Inc. (NYSE MKT: ONVO) announced the sale of 9,425,000 shares of its common stock in an underwritten public offering at a price to the public of $4.25 per share.

Vancouver-based Aspect Biosystems , founded in 2013, announced the closing of an oversubscribed seed round funded by the local Vancouver Angel community.  Like Organovo, Aspect hopes to print human organs.

Cyfuse Biomedical and Cyberdyne signed a $12 million deal to develop and market the Regenova 3D tissue printing system.